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Despite the vigorous research and development, as of 2017, there is currently 
no widely available antimalarial vaccine. An effective, commercially available 
vaccine would be a huge game changer; however, it seems like there is still a 
long way to go until that target is reached. Therefore, the purpose of this study 
was to use molecular docking technique to identify new inhibitors for a novel 
antimalarial target with the overall aim of finding hit compounds which could 
be further optimized to become potential drug candidates. The docking pro-
tocol AutoDockVina was used alongside the molecular visualisation software 
UCSF Chimera to dock 100 naphthoquinones (labelled TM1-100) and 66 aryl 
diketones (labelled TM101-166) with the chosen target, Plasmodium vivax 
N-myristoyltransferase (PvNMT). Each docking session yielded the best 9 
binding modes between the ligand and target. The hydrogen bond interac-
tions of all binding modes were analysed, and the top six target molecules 
(TM) were short listed as the possible hit compounds (TM40, TM65, TM66, 
TM81, TM94 and TM165). These compounds displayed more than six hy-
drogen bonds under 3 angstroms over the 9 binding modes. Using Lipinski’s 
rule of 5, the potential hit compounds were further analysed to determine the 
drug-likeness and all were found to obey the parameters. Following the same 
method used to dock the ligands, twelve FDA approved antimalarial drugs 
were also docked with PvNMT for comparison purposes. Apart from progua-
nil, the other eleven antimalarial drugs displayed fewer hydrogen bonds under 
3 angstroms over the 9 binding modes compared to all six of the potential hit 
compounds. This study discovered six compounds which displayed stronger 
interactions with the target protein compared to majority of the FDA ap-
proved drugs. The results of this investigation gave us new molecules that 
could be further investigated for the designing of novel drug-like compounds 
for the treatment of Malaria. 
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1. Introduction 
A total of 91 countries were considered malaria-endemic in 2016 which is 17 
countries less than in the year 2000 [1]. The number of fatal malaria cases has 
also decreased by more than 40% since 2000 for all World Health Organisation 
(WHO) regions [2]. Despite the incredible reductions, malaria continues to be 
the world’s deadliest parasitic disease. An estimated 216 million cases of malaria 
occurred globally in 2016 alone, including 445,000 fatal cases [1]. A substantial 
portion of these cases (194 million) were reported in the African region which 
has been the case for many years. Children, the elderly and pregnant women are 
at most risk of contracting malaria [3]. This is evident as the majority of the fatal 
cases were reported to be children under the age of five [1]. 
1.1. Aetiology 
Malarial infection is caused by protozoan parasites belonging to the genus Plas-
modium. There are five species of Plasmodium (P), P. falciparum, P. vivax, P. 
ovale, P. malariae and P. knowlesi. Of the five types, P. falciparum is the most 
dangerous and is responsible for majority of the global malarial deaths [1] [3] 
However, the most abundant type is P. vivax with exposure to approximately 2.5 
billion humans across the globe [4]. 
Plasmodium successfully thrives due to its lethal life cycle. The completion of 
this cycle is dependent upon two factors, the female Anopheles mosquito and 
humans [5]. According to Centers for Disease Control and Prevention [5], 
Plasmodium life cycle can be divided into 12 stages, these stages are summarised 
below: 
Plasmodium transmission occurs at stage 1 where an infected mosquito pene-
trates the human skin for a blood meal [3] [5]. Within 30 minutes, the parasite 
travels from the saliva of the mosquito to the host’s liver cells, where it begins to 
rapidly reproduce and eventually enter the blood stream to invade red blood 
cells, stages 2 - 6 [5]. A portion of the parasites invading the red blood cells de-
velop into separate sex cells called gametocytes which are taken up by another 
mosquito during a blood meal, stage 7; this ultimately leads to the production of 
numerous parasitic cells in the mosquito’s salivary gland, stages 8 - 12, thus con-
tinuing the life cycle of the malarial parasite [5]. 
Approved antimalarial drugs exert their effects at different stages of this life 
cycle with the overall aim of diminishing Plasmodium’s abundance within the 
human host. Antimalarial agents will be discussed in detail later. 
Despite the vigorous research and development, as of 2017, there is currently 
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no widely available antimalarial vaccine [6]. This is due to a combination of 
challenges such as the complex nature of Plasmodium’s life cycle, and the 
ever-changing antigens presented by the parasite [7]. An effective, commercially 
available vaccine would be a huge game changer; however, it seems like there is 
still a long way to go until that target is reached. 
1.2. Current Antimalarial Agents 
Antimalarial agents alone can reduce the incidence and prevalence of malaria, 
and they remain at the forefront of malaria control [8] [9]. 
These drugs can be categorized into their two main therapeutic roles. Firstly, 
prompt use of these drugs not only treats an individual but also indirectly stops 
the development of gametocytes (stage 7 of the Plasmodium life cycle) hence 
blocking the spread of malaria. Secondly, antimalarial agents can be used as a 
preventative measure for people visiting or residing in endemic areas [9]. Table 
1 displays the current available drugs grouped into their respective drug classes. 
1.3. Issues Surrounding Antimalarial Drugs 
Although antimalarial drugs have a wide clinical application, they are sur-
rounded by many issues that question their credibility. For many years, chloro-
quine was the gold standard treatment for uncomplicated malaria, however, this 
has drastically changed due to the global spread of chloroquine-resistant falci-
parum and vivax malaria [10]. Amodiaquine 3 and piperaquine 4 have similar 
structural similarities with chloroquine 1, as shown in Figure 1, therefore, these 
drugs are also subject to increasing resistance [9]. 
The naturally occurring quinine 5 is the oldest antimalarial drug dating back 
to the seventeenth century. This drug along with other quinoline-based antima-
larials such as chloroquine 1 and mefloquine 6 have widely reported adverse 
 
Table 1. Current anti malaria drugs. 




















Naphthoquinone Atovaquone (14) 
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Figure 1. Chemical structures of Chloroquine 1; Amodiaquine 2 and Piperaquine 3. 
 
psychiatric effects which includes sleep imbalances, mood changes, impulsivity, 
delusions, hallucinations and also mania; in extreme cases, suicidal thoughts and 
suicides were also reported [11]. Quinine has been known to be very hard to tol-
erate; therefore, its use is limited to severe malaria only [9]. 
Primaquine 4 (Figure 2) was first licensed by the FDA in 1952 and has re-
mained the only drug capable of eliminating dormant parasites residing in the 
host’s liver; unlike the previous quinoline-based drugs, primaquine 4 has rarely 
reported adverse psychiatric effects and is generally tolerable [11]. However, re-
sistance to primaquine 4 has also been observed [12] 
Pyrimethamine 8 was first introduced as a single drug, however, within a 
short period of time, resistance to P. falciparum and P. vivax was observed. 
Therefore, this drug was paired with another antifolate drug named sulfadoxine 
7 which proved effective against chloroquine-resistant malaria, but again, resis-
tance rapidly reappeared [9]. Chemical structures of both agents can be viewed 
in Figure 3. 
More recently, lumefantrine 9 pyronaridine 10 (Figure 4) and some of the 
antimalarial agents mentioned previously have been partnered up with the in-
dispensable artemisinin drugs (Figure 5) to create artemisinin-based combina-
tion therapies (ACT), see Table 2. 
Artemisinins are a valuable set of tools in the battle against malaria. They have 
a quick onset of action and can be administered intravenously to treat individu-
als with severe malaria. The use of artemisinin drugs outside of ACT is highly 
discouraged by the WHO due to the fear of resistance. However, reports of re-
sistance have been reported in South-east Asia [9]. The first reported case of 
ACT-resistance occurred 10 years ago in Cambodia and since then ACT-resistance 
is now predicted to cause over 116,000 deaths globally per annum and cost over 
$32 million per year to treat [13]. 
The atovaquone 14/proguanil 15 (Figure 6) combination (Malarone®), is an 
effective but expensive prophylactic therapy which also has reports of resistance [9]. 
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Figure 2. Chemical structures of Primaquine 4 quinine 5 and mefloquine 6. 
 
 
Figure 3. Chemical structures of Sulfadoxine 7 and Pyrimethamine 8. 
 
 
Figure 4. Chemical structures of Lumefantrine 9 and Pyronaridine 10. 
 
 
Figure 5. Chemical structures of Artemether 11; Artesunate 12 and Dihydroartemisinin 
13. 
7                                                                                                         8
9                                                                                                                 10
11 12 13
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Figure 6. Chemical structures of Atovaquone 14 and Proguanil 15. 
 
Table 2. Artemisinin-based combination therapy (ACT) recommended by WHO. 
Artemether and Lumefantrine 
Artesunate and Amodiaquine 
Artesunate and Mefloquine 
Dihydroartemisinin and Piperaquine 
Artesunate and Pyronaridine 
Artesunate and Sulfadoxine–Pyrimethamine 
1.4. Malarial Resistance 
Almost all antimalarial drugs have reported resistance, which results in a delayed 
or insufficient clearance of Plasmodium in the host’s blood; this may cause pro-
found consequences upon the host’s wellbeing and increases the chances of 
transmission to another host [14]. 
Despite the many attempts by humans to eradicate malaria, Plasmodium has 
always had the ability to mutate and navigate around the actions of antimalarial 
drugs. The urgency to combat resistance has increased as almost all the antima-
larial drugs have recorded cases of resistance which has denounced the once in-
dispensable agents. The race between the development of novel antimalarial 
drugs and the uprising of resistance has intensified, therefore, identifying new 
targets and developing new molecules that can interact with these targets is ur-
gently required in order to produce novel antimalarial drugs [15]. 
1.5. Molecular Docking 
During the last three decades, computational methods have played a major role 
in drug discovery and design; in particular structure-based methods such as mo-
lecular docking has become an important technique [16] [17]. 
Molecular docking studies have been routinely used to better understand cur-
rent antimalarial drugs on the market. A study in 2013 found that quino-
line-based drugs have better binding modes as non-competitive inhibiters than 
as competitive inhibiters to P. falciparum lactate dehydrogenase, a vital enzyme 
the parasite requires for energy [18]. This method has also paved the way for 
14 15
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lead compounds to be considered for pharmaceutical research. A study in India 
found a lead compound with positive docking and pharmacophores features for 
leucine amino peptidase, an enzyme vital for the growth and development of P. 
vivax [19]. 
AutoDockVina is a high speed, popular molecular docking programme which 
is compatible with UCSF Chimera, a molecular visualization software known for 
its numerous functions and capabilities [20] [21]. Both platforms will be at the 
heart of this study. 
1.6. Target Protein 
P. falciparum has been studied intensively due to its high mortality rate, how-
ever, P. vivax is more widely distributed around the world and brings a larger 
social economic burden, therefore, searching for an effective treatment against 
this parasite is also important [4]. 
N-myristoyltransferase (NMT) is an essential enzyme found in P. vivax and 
humans, which catalyses the bonding of a saturated 14-carbon fatty acid named 
myristate to the N-terminal glycine of target proteins; this process is called 
myristoylation [22]. A number of essential proteins such as protein kinase 1 and 
glideosome found in malarial parasites need to undergo myristoylation to carry 
out their biological functions, therefore, by inhibiting NMT, the parasite should 
fail to thrive [23]. Variations between parasitic and human NMT makes it a 
highly promising selective target [24]. 
Several published studies have aimed to discover potential inhibitors of Plas-
modium vivax (Pv) NMT. A United Kingdom study in 2012 successfully discov-
ered a hit compound named  
3-butyl-4-((2-cyanoethyl)thio)-6-methoxy-2-methyl-quinoline using a high 
throughput screening technique involving a fluorogenic assay [24]. A similar 
study in the same year tested benzothiophene containing inhibitors using struc-
ture activity relationship techniques and discovered a lead compound for further 
development [23]. 
There are several published studies involving PfNMT, however, the current 
lack of molecular docking studies involving PvNMT has encouraged this study 
to pursue this as the target protein of interest. The 3D structure of PvNMT 
(Figure 7). 
The overall aim of this study was to prepare and evaluate a series of naphtho-
quinone and aryl diketone ligands for potential use as PvNMT inhibitors using 
computational docking techniques. 
2. Materials and Methods 
The chemical diaries of Napthoquinones and diketones were used for the pur-
pose of this screening, because the Napthoquinones and diketones have phar-
macophores that worthy of further investigations. Naphthoquinones have 
been found to be active towards some cancer, and diketones are very good  
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Figure 7. 3D structure of Plasmodium vivax N-myristoyltransferase, 
PDB ID: 5G22 [25]. 
 
anti-microbial activities. The structures of Napthoquinones and diketones used 
for this docking investigation were obtained from the NCBI Pub-Chem data-
base. 
2.1. Target Protein and Ligand Selection 
A range of ligands will be docked against PvNMT to yield an array of results. 
Firstly, naphthoquinone compounds will be docked to the target protein as they 
have been known to possess antimalarial activity [26]. There is an antimalarial 
drug currently on the market called atovaquone that belongs to the class of 
naphthoquinones, therefore, these compounds are a promising choice as ligands. 
Aromatic diketones, cromolyn and FDA approved antimalarial drugs will also be 
docked with PvNMT for comparison purposes. 
The three-dimensional structure of P. vivax N-myristoyltransferase was 
downloaded as a PDB file from the RCSB Protein Data Bank (PDB ID: 5G22). 
This protein was opened in Auto Dock Tools version 1.5.6 where the co-ordinates 
of the binding pocket were determined using the grid box function. The figures 
used are shown below in Table 3. 
The PDB file of the protein was opened in UCSF Chimera version 1.12 and all 
non-standard atoms and bonds were removed. Using the dock prep function, 
water molecules were deleted, partial charges were assigned and hydrogens were 
added to the protein. The protein was then saved in the Mol 2 format ready for 
the docking stage. 
2.2. Ligand Preparation 
The naphthoquinones and aryl diketones compounds on PubChem were long-
listed for the docking stage. The canonical SMILES of the compounds were  
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Table 3. Co-ordinates of the binding pocket for the target protein. 
 Size Centre 
X dimension 20 17 
Y dimension 28 12 
Z dimension 30 62 
 
entered into UCSF Chimera using the build structure tool. The compound was 
then prepared by adding hydrogens using the structure editing function and 
moved the system towards its minimized energy using the minimize structure 
tool. The ligand was named “target molecule #” and saved in the Mol2 format 
ready for the docking stage. 
2.3. Molecular Docking 
On a new UCSF Chimera session, firstly, the Mol2 file of the protein was opened 
followed by the target moleculea. Using the structure/binding analysis tool, the 
AutoDockvina function was opened. The PDB format of the protein was selected 
as the receptor and the SMILES of the target molecule was selected as the ligand. 
An output file was created and the co-ordinates of the binding pocket, as shown 
in Table 3 was entered. All receptor and ligand options were set as true and the 
exhaustiveness of search was set at the maximum of 8. Also, the number of 
binding modes was selected as 9. Vina.exe via a local path was chosen as the ex-
ecutable location and docking was applied. All naphthoquinone and aryl dike-
tone compounds were docked with P. vivax N-myristoyltransferase by following 
this method. 
2.4. Docking Analysis 
Analysis was carried out for all docking sessions on UCSF Chimera. All in-
tra-residue hydrogen bonds were made visible by altering the hydrogen bond 
function on Chimera. The line width was kept at the default 4.0, however, the 
number of angstroms was altered to 3.0. Applying these changes displayed all 
hydrogen bonds (less than approximately 5 angstroms) between the protein and 
the 9 binding modes of the ligand. Each of the nine binding modes for all 166 
ligands were analysed for any hydrogen bond(s) less than 3 angstroms. The 
amino acid residue involved in the hydrogen bond, its position and the number 
of angstroms of the bond were all recorded during the docking analysis phase. 
3. Data Analysis 
3.1. Binding Mode Analysis 
Binding mode analysis were carried out for all docking sessions by relaunching 
the python files on UCSF Chimera. All intra-residue hydrogen bonds were made 
visible by altering the hydrogen bond function on Chimera. The line width was 
kept at the default 4.0, however, the number of angstroms was altered to 3.0. 
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Applying these changes displayed all hydrogen bonds (less than approximately 5 
angstroms) between the target protein and ligand across the 9 binding modes. 
Angstroms is a unit of length equivalent to 0.1 nanometres and as the shorter 
the length of a hydrogen bond results in a stronger interaction, finding bonds 
with short angstroms will identify binding modes with good affinity [27]. By 
hovering over a hydrogen bond, the number of angstroms as well as the name 
and position of the amino acid involved in the bond were found (Figure 8). All 
hydrogen bonds across the 9 binding modes for all 166 ligands were analysed for 
any hydrogen bond(s) less than 3 angstroms. The amino acid residue involved in 
these hydrogen bonds, its position and the number of angstroms of the bond 
were recorded. 
These data was collated and evaluated on Microsoft Excel and the short-listing 
process was undertaken to identify hit compounds. 
3.2. Docking Scores Analysis 
As well as generating binding modes, AutoDockVina also uses a combination of 
knowledge-based and empirical scoring functions to predict the binding affini-
ties of the ligands to the target protein; this is represented as the docking score 
[28]. These figures were obtained for the short-listed hit compounds from the 
View Dock window on UCSF Chimera (Figure 9). These data was collated and 
evaluated. 
Christopher Lipinski formulated a tool named the rule of five (Ro5) to evalu-
ate the drug-likeness of chemical compounds; he based this rule on the basis that 
most orally delivered drugs are small and moderately lipophilic molecules [29]. 
By obtaining the Ro5 parameters, the drug-likeness of the hit compounds was 
studied. This involved acquiring molecular weights from PubChem and cLogP 
values from an online software called ALOGPS 2.1. Also, the hydrogen bond 
donors (HBD) and hydrogen bond acceptors (HBA) for each binding mode dis-
playing hydrogens under 3 angstroms were recorded from ViewDock. 
Twelve FDA approved antimalarial drugs were also docked with PvNMT by 
following the same method used to dock the 166 ligands (Section 2.3). The hy-
drogen bond interactions and docking scores data were also obtained, recorded 
and evaluated by following the same methods (Sections 3.1 and 3.2). This data 
was used for comparative purposes. 
 
 
Figure 8. Visualisation of the information gathered from the hydrogen bonds. 
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Figure 9. Number of target molecules displaying 0 - 9 hydrogen bonds (<3Å) across all 
binding modes with PvNMTData acquired via binding mode analysis on AutoDockVina, 
see Section 3.1. 
4. Results 
4.1. Potential Hit Compounds Identification 
All 166 target molecules, (labelled TM1-100 for naphthoquinones and TM101-166 
for aryl diketones) were successfully docked to PvNMT. Analysis of the binding 
modes revealed a range in the number of hydrogen bonds below 3 angstroms 
(Å) between the set. Figure 10 displays this data and reveals 69 of the 166 target 
molecules (42%) displayed a lack of hydrogen bonds under 3Å. Therefore, the 
deduction can be made that these ligands have a lack of strong interactions with 
PvNMT. 
The remaining 97 target molecules (58%) displayed at least one hydrogen 
bond (<3Å) across the 9 binding modes. As the number of the hydrogen bonds 
(<3Å) increases, the strength of the interactions also increases. Therefore, 
ligands with the highest number of hydrogen bonds (<3Å) were short-listed as 
potential hit compounds. 
Figure 9 shows that the number of target molecules decreases with increasing 
hydrogen bonds (<3Å). This facilitated the short-listing process. Out of the 166 
target molecules, six displayed more than 6 hydrogen bonds (<3Å) with PvNMT 
and were shortlisted as the top six hit compounds. The chemical structures of 
the hit compounds are shown in Figure 10. 
4.2. Analysis of the Binding Modes 
4.2.1. Potential Hit Compound Analysis 
Further analysis of the binding modes were undertaken and the number of hy-
drogen bonds (<3Å) for the individual binding modes as well as the name and 
position of the amino acid residue involved in the hydrogen bond was obtained 
and recorded (Table 4). A total of 44 hydrogen bonds (<3Å) were observed 
across the six hit compounds. 
The range of the amino acid residues involved in these observed hydrogen 
bonds are shown in Figure 11. A total of 10 different amino acids at 17 different 
position were involved. Glutamic acid (789.C), serine (245.A) and threonine 
(315.A) shared a total of 28 out of the 44 hydrogen bonds (64%), which marks  
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Figure 10. Chemical structures of the 6 hit compounds, TM94 16, TM6 617, TM165 18; 
TM40 19; TM6520; and TM81 21. 
 
 
Figure 11. The number of potential hit compound hydrogen bonds (<3Å) with PvNMTs 
residue. 
 
these residue positions as hydrogen bonding hot spots. This data was used to re-
search whether these hit compounds were binding to a recognised essential 
amino acid. 
As of late 2017, there is a lack of data regarding the specific roles of these 
amino acid residues within PvNMT. If glutamic acid (789.C), serine (245.A) and 
threonine (315.A) were found to be essential amino acids which the enzyme re-
quires to function, therefore, the hit compounds could be selectively targeting an 
ideal location. 
By comparing the potential hit compounds between themselves, TM165 dis-
played the highest total number of hydrogen (9) bonds (<3Å) across the 9 bind-
ing modes. However, TM40 displayed the highest total number hydrogen (3) 





















Name and position of the PvNMT's residue interacting with the hit compounds 
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Table 4. The number of hydrogen bonds (<3Å) for the six potential hit compounds including the name and position of the inter-







Total number of 
hydrogen bonds 
below 3 angstroms 
Number of  
hydrogen bonds 
(<3Å) at each pose 
Name and position of the enzyme’s 
residue interacting with the target  






1 GLU 728.B (2.158) 
6 2 PHE 403.B (2.955) + LYS 321.A (1.877) 
7 3 
SER 349.A (2.410) + LYS 321.A (1.867) + 
PHE 320.A (2.335) 
8 1 GLU 728.B (2.279) 






1 THR 315.A (2.909) 
4 2 GLU 789.C (2.415) + GLU 789.C (2.622) 
5 2 GLN 249.A (2.891) + TYR 246.A (2.544) 






1 SER 245.A (2.695) 
3 1 SER 245.A (2.588) 
4 2 SER 245.A (2.590) + THR 315.A (2.158) 
5 1 GLN 634.B (1.962) 
6 1 SER 245.A (1.911) 
7 1 SER 245.A (2.028) 




1 GLU 789.C (2.179) 
2 2 PHE 641.B (2.120) + HIS 625.B (2.379) 
5 1 PHE 256.A (2.117) 
7 1 GLU 789.C (2.323) 








1 GLU 789.C (2.442) 
5 1 SER 245.A (2.180) 
6 1 SER 245.A (2.093) 
7 2 SER 245.A (2.210) + GLU 789.C (2.313) 
8 1 SER 245.A (2.394) 









2 THR 315.A (2.885) + THR 315.A (2.304) 
2 1 GLU 789.C (2.453) 
3 2 GLU 789.C (2.789) + SER 245.A (1.953) 
4 1 THR 315.A (2.269) 
6 1 THR 315.A (2.160) 
8 1 SER 245.A (2.124) 
9 1 LEU 242.A (2.000) 
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angstroms (4.335Å and 5.436Å). This binding mode also recorded the hydrogen 
bond with the lowest angstrom (1.867Å) compared to all the 44 observed hy-
drogen bonds. 
Figures 12-17 display the binding mode for each potential hit compounds 
which displayed the highest number of hydrogen bonds (<3Å) with the lowest 
angstroms. 
4.2.2. Comparison with FDA Approved Antimalarial 
As explained in section 3.2, 12 antimalarial drugs were docked and analysed fol-
lowing the same methods used for the ligands. Out of the 12 drugs, eleven dis-
played a lower number of hydrogen bonds (<3Å) across the 9 binding modes 
compared to the six potential hit compounds, as shown in Table 5. The hit 
compounds displayed 6 or more hydrogen bonds (<3Å), whereas the highest of 
these eleven drugs displayed only 4 (primaquine and pyrimethamine). 
 
 
Figure 12. The hydrogen bonds (<3Å) for TM40, pose 7. 
 
 
Figure 13. The hydrogen bonds (<3Å) for TM65, pose 4. 
K. Adebambo, S. Gunaratnam 
 
 
DOI: 10.4236/cmb.2018.82002 57 Computational Molecular Bioscience 
 
 
Figure 14. The hydrogen bonds (<3Å) for TM66, pose 4. 
 
 
Figure 15. The hydrogen bonds (<3Å) for TM81, pose 2. 
 
 
Figure 16. The hydrogen bonds (<3Å) for TM94, pose 7. 
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Figure 17. The hydrogen bonds (<3Å) for TM165, pose 3. 
 
However, proguanil outperformed not only the other 11 drugs but also the 6 
potential hit compounds by displaying 10 hydrogen bonds (<3Å) across the 9 
binding modes. The fourth binding mode for proguanil displayed three of these 
bonds and are shown in Figure 18. 
The varying binding locations between the potential hit compounds and 
proguanil must be noted. As explained in the previous section, the hit com-
pounds predominately interacted with glutamic acid (789.C), serine (245.A) and 
threonine (315.A), whereas progunail does not. The antifolate drug instead 
mainly interacted with lysine (241.A) and leucine (242.A). 
4.2.3. Docking Scores Analysis 
The docking scores for the binding modes of the shortlisted compounds and the 
12 FDA approved drugs which displayed hydrogen bonds (<3Å) are listed in 
Table 6. The scores are listed in ascending order as the lower docking scores are 
generated by the more active ligands [30]. All seven of TM165’s observed bind-
ing modes had the best docking scores indicating that this ligand was calculated 
to have the best binding affinity out of all the hit compounds. 
The poses which displayed the highest number of hydrogen bonds (<3Å) with 
the lowest angstroms did not correlate with the docking scores. Pose 7 of TM94 
displayed two hydrogen bonds (<3Å) which is double of any other pose, how-
ever, TM94_7 generated the lowest docking score. Similarly, proguanil generated 
a docking score in the lower half of the docking score range. 
In determining the docking for the poses, ideally the poses with RMSD value 
of zero for both lower and upper bounds should be deemed to have highest 
binding affinity, but, it must be noted that the docking scoring function has 
conventionally been associated with poor accuracy, which renders it one of the 
most important limitation of molecular docking [28]. This may explain the poor 
correlation. 
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Table 5. Number of hydrogen bonds (< 3Å) between FDA approved drugs and PvNMT 
Drug class Drug name 
Number of  
hydrogen bonds (<3Å) 
Conformation 
Name and position of the enzyme’s residue 
interacting with the target molecule  
including (angstroms, Å) 
4-aminoquinoline 
Chloroquine 1 7 GLU 789.C (2.908) 
Amodiaquine 2 
2 LEU 242.A (2.985) 
6 LEU 242.A (2.095) 
8-aminoquinoline Primaquine 4 
3 TYR 246.A (2.753) 
4 SER 245.A (2.246) 
5 TYR 246.A (2.962) + SER 245.A (2.429) 
Arylamino alcohol Mefloquine 3 
1 LEU 242.A (2.428) 
4 THR 315.A (2.129) 
7 SER 245.A (2.643) 
Sesquiterpene lactone 
endoperoxides 
Artemether 0   
Artesunate 2 5 TYR 246.A (2.574) + SER 245.A (2.139) 
Dihydroartemisinin 0   
Antifolate 
Pyrimethamine 4 
3 SER 245.A (2.012) 
4 SER 245.A (2.402) 
8 SER 245.A (2.703) 
9 THR 315.A (2.228) 
Sulfadoxine 3 
1 ILE 283.A (2.214) 
2 ALA 639.B (2.559) 
9 LEU 242.A (2.239) 
Proguanil 10 
1 LYS 241.A (2.363) + LEU 242.A (2.032) 
2 LEU 242.A (2.570) 
4 
LYS 241.A (2.522) + LEU 242.A (2.834) + 
LEU 242.A (2.021) 
5 ALA 763.B (2.241) + GLN 634.B (2.578) 
8 GLN 249.A (2.230) + ALA 378.A (2.937) 
Naphthoquinone Atovaquone 0   
Antibiotic Doxycycline 3 
4 GLN 634.B (2.147) 
7 SER 245.A (2.506) 
9 THR 315.A (2.577) 
4.2.4. Drug-Likeness of the Hit Compounds 
The four components that form Lipinski’s Ro5 is shown in Figure 19. 
This rule was applied to the six shortlisted compounds and Table 7 shows that 
all potential hit compounds obeyed the Ro5 with no violations. This indicates 
that these compounds possess favourable characteristics to become orally active 
drugs. 
The molecular mass of TM165 was on the upper end of the limit with a mo-
lecular weight of 475.5 g/mol (1 g/mol ≅ 1 Dalton), which is 25 Daltons from a 
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Figure 18. The hydrogen bonds (<3Å) for proguanil, pose 4. 
 
 
Figure 19. The components of Lipinski’s rule [29]. 
 
violation. Exceeding the parameters may have a negative impact upon absorp-
tion and permeation compared to the other hit compounds [29]. The other pa-
rameters for all hit compounds were well within the Ro5 limits. 
This section has presented evidence for six potential hit compounds as prom-
ising candidates as potential PvNMT inhibitors. The rationale behind shortlist-
ing these candidates from 166 target molecules was explored. This was followed 
by displaying the compounds’ superior hydrogen bonding compared to the  
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Table 6. The docking scores for the poses of the six shortlisted compounds and docked 
antimalarial drugs with hydrogen bonds < 3Å in ascending order. 
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majority of the docked FDA approved drugs. Furthermore, the drug-likeness of 
all potential hit compounds was confirmed by using the Lipinski’s Ro5. 
4.3. Strengths and Limitations 
The strengths and limitations of this study lies with the largest variable of this 
study, the molecular docking technique. AutoDockVina was the chosen docking 
software in this study, however, there are more than 60 developed docking tools 
available; some examples include DOCK, MOE, AutoDock and GOLD (Pa-
gadala, Syed and Tuszynski, 2017). AutoDockVina was released in 2010 as a 
successor to AutoDock; the upgrade was promoted to possess twice the speed 
and an improved binding mode accuracy compared to its predecessor [21]. 
All docking softwares including AutoDockVina are subject to the universal 
limitations of molecular docking. A major weakness is the accuracy of the scor-
ing function which is one of the most important component of this computa-
tional technique. Various software’s utilise different scoring function techniques 
such as empirical, force-field and knowledge-based, which all carry limitations. 
However, several comparative studies have promoted the accuracy of Auto-
DockVina. A recent comparative study of docking softwares ranked AutoDock-
Vina along with GOLD and MOE as the best tools for accurate prediction of 
ranking poses with the best docking scores [31]. 
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Number of hydrogen 
bond donors 
Number of hydrogen 
bond acceptors 
CLogP range 
TM40 4-aminonaphthalene-1,2-dione 173.171 
Pose 4 1 Pose 4 1 
1.55 - 2.43 
Pose 6 3 Pose 6 3 
Pose 7 3 Pose 7 3 
Pose 8 2 Pose 8 2 
Pose 9 1 Pose 9 1 
TM65 3,4-dioxonaphthalene-1-sulfonic acid 238.213 
Pose 1 2 Pose 1 2 
−0.55 - 2.77 
Pose 4 2 Pose 4 1 
Pose 5 2 Pose 5 2 
Pose 7 2 Pose 7 3 
TM66 4,8-diamino-2,6-dibromonaphthalene-1,5-dione 345.978 
Pose 1 1 Pose 1 1 
1.28 - 3.51 
Pose 3 1 Pose 3 1 
Pose 4 2 Pose 4 2 
Pose 5 1 Pose 5 1 
Pose 6 1 Pose 6 1 
Pose 7 2 Pose 7 2 
Pose 9 1 Pose 9 1 
TM81 2-nitrosonaphthalen-1-ol 173.171 
Pose 1 1 Pose 1 1 
2.43 - 2.70 
Pose 2 2 Pose 2 2 
Pose 5 1 Pose 5 1 
Pose 7 2 Pose 7 2 





Pose 1 1 Pose 1 1 
2.36 - 3.56 
Pose 5 1 Pose 5 1 
Pose 6 1 Pose 6 1 
Pose 7 2 Pose 7 2 
Pose 8 1 Pose 8 1 






Pose 1 3 Pose 1 3 
2.62 - 3.88 
Pose 2 2 Pose 2 2 
Pose 3 4 Pose 3 5 
Pose 4 1 Pose 4 1 
Pose 6 2 Pose 6 3 
Pose 8 3 Pose 8 3 
Pose 9 3 Pose 9 3 
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5. Conclusions 
The six compounds presented similarities and differences to previously discov-
ered inhibitors. Published hit compounds possessed a common pharmacophore 
of primary, secondary and tertiary amines [32]. This coincides with the majority 
of the six potential hit compounds generated from this study as five of the six 
compounds (TM40, TM66, TM81, TM94 and TM165) possess either primary, 
secondary or tertiary amines. This pattern is however not widely consistent as 
NMT inhibitors are known to display diverse binding modes which result in a 
range of different pharmacophores; this may explain the absence of these phar-
macophores in TM65 [32]. 
The twelve FDA approved antimalarials were docked with PvNMT even 
though they are not known to exert their action on this target protein. However, 
using currently marketed drugs as starting points in drug discovery provides a 
better practical and cheaper alternative compared to untested synthetic com-
pounds [33]. The comparison of hydrogen bond interactions between the hit 
compounds and FDA approved drugs were analysed and the six shortlisted 
compounds were found to perform better than eleven of the twelve drugs. How-
ever, proguanil out performed all hit compounds and FDA approved drugs. 
The varying binding locations between the potential hit compounds and 
proguanil must be noted. The potential hit compounds predominately interacted 
with glutamic acid (789.C), serine (245.A) and threonine (315.A), whereas pro-
gunailmainly interacted with lysine (241.A) and leucine (242.A). This finding 
shows that the six potential hit compounds displayed stronger hydrogen bonds 
at different locations compared to the 12 FDA approved antimalarial agents. 
This is important as drugs that exert their action at different locations of the 
target protein can lower the incidence of drug resistance. This forms the basis 
behind the originality of the potential hit compounds, and strengthens the case 
for using these compounds as starting points for development. 
Furthermore, none of the shortlisted compounds violated any of the Lipinski’s 
Ro5 parameters. This is a positive indication that these compounds not only 
show promising interactions, but also possess ideal characteristics to become de-
sirable orally active therapeutic agents. 
The potential hit compounds found in this study increases the number of po-
tential inhibitors for PvNMT As discussed in the previous section, these com-
pounds can also aid further validation of PvNMT as an ideal target protein by 
demonstrating selective inhibition which subsequently results in reductions in 
Plasmodium in human blood. Moreover, subject to further development, these 
compounds possess the potential to become hit compounds, which can be de-
veloped to Lead compounds and eventual antimalarial drugs. A novel therapeu-
tic agent would be a huge leap forward in the race against antimalarial resis-
tance. 
In the event of these compounds demonstrating selective inhibition of Pv 
NMT with subsequent reductions in Plasmodium in the blood, then this protein 
will be further validated as a drug target. 
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Finally, even though there is no single docking program which has dominative 
benefits above others, as all are subject to the universal molecular docking limi-
tations. However, the results generated from AutoDockVina has been proved to 
be a reliable choice compared to the other docking softwares and this give credi-
bility to the six shortlisted compounds that we obtained during the course of this 
research. The aim of this study was met as six potential hit compounds were 
discovered. 
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